The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 01, 2022

Filed:

Aug. 18, 2017
Applicant:

Guangzhou Virotech Pharmaceutical Co., Ltd., Guangdong, CN;

Inventors:

Guangmei Yan, Guangzhou, CN;

Haipeng Zhang, Guangzhou, CN;

Yuan Lin, Guangzhou, CN;

Suizhen Lin, Guangzhou, CN;

Jing Cai, Guangzhou, CN;

Shoufang Gong, Guangzhou, CN;

Jun Hu, Guangzhou, CN;

Xiao Xiao, Guangzhou, CN;

Kai Li, Guangzhou, CN;

Jiankai Liang, Guangzhou, CN;

Yaqian Tan, Guangzhou, CN;

Wenbo Zhu, Guangzhou, CN;

Wei Yin, Guangzhou, CN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/00 (2006.01); A61K 31/4439 (2006.01); A61K 31/444 (2006.01); C12N 7/00 (2006.01); A61K 31/4178 (2006.01); A61P 35/00 (2006.01); A61K 35/768 (2015.01); A61K 45/06 (2006.01); A61K 48/00 (2006.01); A61K 9/00 (2006.01); A61K 9/19 (2006.01); A61K 9/48 (2006.01); A61K 9/70 (2006.01); A61K 31/519 (2006.01); A61K 31/7105 (2006.01); A61K 31/713 (2006.01); A61K 38/17 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4178 (2013.01); A61K 9/0019 (2013.01); A61K 9/19 (2013.01); A61K 9/48 (2013.01); A61K 9/7023 (2013.01); A61K 31/00 (2013.01); A61K 31/4439 (2013.01); A61K 31/519 (2013.01); A61K 35/768 (2013.01); A61K 45/06 (2013.01); A61K 48/00 (2013.01); A61P 35/00 (2018.01); C12N 7/00 (2013.01); A61K 31/713 (2013.01); A61K 31/7105 (2013.01); A61K 38/1774 (2013.01); C12N 2770/36132 (2013.01);
Abstract

The present invention belongs to the field of biomedicine and relates to use of VCP (valosin-containing protein, VCP) inhibitor and oncolytic virus in the preparation of an anti-tumor drug. The present invention firstly discovers that VCP inhibitor can be used in the preparation of an anti-tumor synergist for oncolytic virus. Meanwhile, the present invention relates to a pharmaceutical composition comprising VCP inhibitor and oncolytic virus, a pharmaceutical kit comprising VCP inhibitor and oncolytic virus, and use of VCP inhibitor and oncolytic virus for treating tumor, especially a tumor that is not sensitive to oncolytic virus. The present invention also relates to an anti-tumor administration system, characterized in that, comprising oncolytic virus and a reagent for detecting the expression level of VCP.


Find Patent Forward Citations

Loading…